Member Info for sadoldgit

Good morning Brighty1.

I doubt very much BMS would buy as they have SOTYKTU.

Safety data is crucial. There will be no problem with it not being satisfactory just a case of any adverse events.

No SAE'S potentially on the info that Tim and Co have so far and that is up to 300mg per day.

In a sense at the moment we have no MTD.

A nice problem to have said Tim

Contributed to problems with the MHRA l would suggest but as for now a very very nice problem to have.

Psoriasis should be nailed, and other optimum Indications that 1801 should prove to be of benefit ought to be known by Tim and Co now.

Deucravacitinib? Apart from.a very good safety profile what else has it got going for it?

A dual inhibitor with similar safety profile should be worth far more than Deucravacitinib. That is of course at later phase trials. Patent protection coming on fine.

What do Sareum announce first after safety data results?

Entering in to phase 2 trial ( and this need be only a phase 2a) or we are pleased to announce we have entered onto a partnership/ on licence of mediocre upfront payment with very high milestones?

That my feelings as to where we stand.

Regards

Acrivon had no problem and in fact were oversubscribed in raising 130 mullion dollars.

They have a Wee1 inhibitor but are fast tracked in a couple of Indications for prexasertib. Areas of unmet need

Also interesting if we delve much deeper and the use of B family polymerase in combo.

Indeed this Michelle Garrett was much involved in this circa 2019 2020.

Trials were stopped short. Not because of any problems with the therapy but due to covid 19 causing the cessation of drug production for clinical trial

Pipeline below and as l say, although not mentioned in the pipeline 130 millipn raised with no problems.

Regards

https://acrivon.com/pipeline/#pipeline

The following snippet is taken from a link is dated 22nd Nov 2023

The currently marketed Chk1 inhibitors include:

CCT-245737

LY-2880070

Prexasertib Mesylate Hydrate

BBI-355

BEBT-260

PEP07

Piricopril acetate

RG-7741

XCCS605B

XS-02

Interesting to note CCT245737 and not SRA737.

On the release of satisfactory data it will not be long before we are a phase 2 candidate.

The importance is on the data and is critical.

There will be know problem with severe adverse events at these doses.

They are on effect 30% of the maximum therapeutic dose stated by Sareum.

Now the good thing is at these levels the therapeutic range has been hit dhich l believe Sareum were pleasantly surprised by.

So we have a Tyk2 Jak 1 inhibitor that has potentially greater efficacy in Psoriasis with what should be a similar safety profile.

In addition to the Tyk2 we have Jak 1 which should prove far better in other Indications that Deucracitinib flunked in.

Deucracitinib was hailed as the be all and end all, based on a very good satisfactory safety profile.

Yes allosteric TyK2 via JH 2 domain which controls the active site JH1.

Marvellous, it ain't that good in Psoriasis and failed to meet either of its end points in Ulcerative Colitus.

Rather like you having your feet on fire and you go pi55ing over the boots of the person standing next to you.

Take a read over at ADzvN at a couple of the mongs who post.

20 year old drug

Sarfum going to collapse.

MHRA refused it due to it being old and even with an established experienced CRO that formulated the capsule it was not considered safe to give to patients.

Fools. Not least the one who claimed he sold at the peak and at the same time claims sareum are so bad and inept.

I think ot bought at a peak and sold at a loss.

The other idiot claims to put valid arguments which he states people on the ADVN cannot give an answer

If they want to pit argument forward here they are welcome to fo so. They have lost in the past.

They then get shirty and insulting which results in a ban. Just take a read at the drivel they put.

Sareum will now go from strength to strength and there is absolutely nothing they can do about it.

More chance of this share going to 800 million market cap than the 8 million prior to complete failure that they forecast.

Have a good weekend all, we are rapidly approaching news time.

Level 2 l believe showed buys at 31 and 32p entered at 16.50 and 16.51

There is no reason as to why the results should not be very good.

Indicative so far in the RNS that "potentially no serious adverse events.'

That should give a close a clue as you will get as to the final expectation of results 1a data.

Nice blue sky and nice blue rise, it we still sit very low with regards to SP. Market Cap around 31 million.

Should RF not have any shares left, then a gradual climb north next week should be on the cards.

Regards and a good weekend to all.

Whst news would that be then?

Imminent news if 1801 trial results?

30p buy coming up soon too.

Should hit 29p buy soon!

You will be lucky. Another 1600 at 3rd attempt H&L , no problem selling for those that want.

Good morning bailiff.

Most l could get was 1600. Unless Riverfort have a few to add then SP will increase.

Success on a piddly 1600!

I have tried 3 times to add and unable to do so through LH this am.

Deucravacitinib is the first Tyk2 inhibitor to be authorised for use in patients.

A new drug is defined is a drug that has not reached authorised approval for use in the clinic and indeed is still considered new up to 6 months post commercialisation.

That is as near as l can define.

The 4 kinase inhibitors known about for many years. This is not of any relevance whatsoever.

What is important is the selectivity and complexity of the compounds to enable a satisfactory safety profile, along with sufficient efficacy that prove to give greater benefit than the current available 1st in line treatments.

Deucravacitinib is a first in class, that is entirely different to best in class, so much so that there are now many Tyk2 selective inhibitors along with the addition Jak1 and Jak2 in various stages of development.

SdC1801 we await safety data results and interpretation thereof.

'Potential no adverse severe side effects at therapeutic dosage levels'

Note, not little to no, but no severe adverse effects.

300 grammes per day maximum given in trial.

30% of maximum therapeutic daily dose as initially proposed by Sareum

Regards

Interesting read Nov 23 in link below.

https://synapse.patsnap.com/blog/what-are-chk1-inhibitors-and-how-do-you-quickly-get-the-latest-development-progress

Vet pertinent and easily over looked regarding 1801.

'Preliminary blinded safety, tolerability and pharmacokinetics data from the trial indicate a favourable profile and support once daily oral dosing of patients.

· These preliminary results indicate that SDC-1801 has the potential to achieve therapeutically effective dose levels with no serious adverse events.'

Note it does not say little to no serious adverse events, but no adverse events.

Attention to detail is paying off.

Effectively, what limits the effectiveness of a drug is its safety profile, the effectiveness is limited by dose tolerance.

Safety is of the upmost importance and if not adequate will be counter productive to the benefits of efficacy.

'In preclinical the compound was tested at over 30 times treatment dose with no observed adverse events.

Phase 1 a completed biomarker and PK data results to indicate areas of potential best treatment.

A lot of attention to detail gone in to getting the compound right.

Nobody suggested the J&J psoriasis treatment would be withdrawn

However, how will J&J replace the revenue lost when the treatment will become generic due to patent expiry?

Yes Potnak they will forward sell as is not an uncommon practice.

They have tried their hardest to destroy the company.

Https://www.fiercepharma.com/special-report/top-15-blockbuster-patent-expirations-coming-decade